We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| 4d Pharma Plc | LSE:DDDD | London | Ordinary Share | GB00BJL5BR07 | ORD 0.25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 16.36 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMDDDD
RNS Number : 4105G
4d Pharma PLC
26 May 2017
4D pharma plc
(the "Company" or "4D")
Result of AGM
At the annual general meeting of 4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, held earlier today, all resolutions put to shareholders were duly passed.
The full text of each resolution was included in the notice of the meeting, which was posted to shareholders on 2 May 2017, and is available on the Company's website www.4dpharmaplc.com.
For further information please contact:
4D + 44 (0)113 895 0130 Duncan Peyton, Chief Executive Officer Zeus Capital Limited - Nomad and Joint Broker Dan Bate +44 (0) 161 831 1512 Dominic Wilson +44 (0) 203 829 5000 Investec Bank plc - Joint Broker +44 (0) 207 597 5970 Patrick Robb Daniel Adams Carlton Nelson
About 4D
Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D currently has a pipeline of 13 preclinical programmes, covering disease areas such as rheumatoid arthritis, multiple sclerosis and cancer, and is currently conducting subject trials in Irritable Bowel Syndrome and Paediatric Crohn's Disease. The programmes in Paediatric Ulcerative Colitis and Paediatric Crohn's Disease have both been granted Orphan Drug Status by the FDA.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGBDGDUIUDBGRL
(END) Dow Jones Newswires
May 26, 2017 08:59 ET (12:59 GMT)
1 Year 4d Pharma Chart |
1 Month 4d Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
